by Brothers et al. at the same conference, involving data from more than 9000 patients in 37 clinical trials, shows an overall rate of suspected hypersensitivity of 5.4% (5). Although the result of the unplanned Fisher's exact test reported by James et al. in Zodiac, comparing the frequency of grade 3/4 suspected HSRs in the ABC once-daily vs. the ABC twice-daily arms, is p ¼ 0.02 (5 vs. 2%), it is important to note that the exact confidence intervals around each of these proportions overlap (95% CI ¼ 3.0-7.6% and 0.7-3.7%). The interpretation of this unplanned statistical test should be made with caution. In fact, no significant differences in grade 3/4 HSRs, hospitalisations or deaths attributed to HSR were seen in the ABC once-daily vs. twice-daily arms of six large studies (6), consistent with the lack of a biological rationale for a higher rate or severity of HSR when ABC is given as 600 mg once daily vs. 300 mg twice daily. 
